Loading grant details…
Using COVID-19 vaccine technology to treat type 1 diabetes
| Funder | Dutch Research Council |
|---|---|
| Recipient Organization | Azl Lumc |
| Country | Based in EU |
| Start Date | Oct 01, 2022 |
| End Date | Dec 30, 2023 |
| Duration | 455 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | OCENW.XS22.2.001 |
Grant Description
mRNA technology has the potential to revolutionize the field of regenerative medicine, as it is possible to easily synthesize a large variety of mRNAs that may be used to express any protein of interest.
However, because of its immunogenicity and lack of stability, mRNA has mostly been unable to serve as a therapeutic agent up to now.
A great deal of effort has been spent on synthetic mRNA modification approaches to overcome these limitations, especially evident during the pandemic.
In this innovative project, we propose using COVID-19 vaccine technology to produce insulin-producing β-cells suited for type 1 diabetes therapy
All Grantees
Azl Lumc
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
